Humacyte, Inc. filings document a commercial-stage biotechnology issuer built around acellular tissue engineered vessels and related bioengineered human tissue programs. Its reports and 8-K filings cover operating results, product commercialization, clinical and regulatory disclosures, material agreements for Symvess distribution rights, and collaboration or licensing arrangements.
The company’s SEC record also includes capital-structure disclosures for common stock and redeemable warrants, equity offering arrangements, secured debt financing, and Nasdaq listing-rule notices. Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and other governance disclosures for HUMA.
Humacyte, Inc. (HUMA) reported a stock option award to its President, CEO and Director, Laura E. Niklason. On November 16, 2025, she was granted stock options to purchase 311,100 shares of Humacyte common stock at an exercise price of $1.23 per share, expiring on November 16, 2035. The options vest in three equal installments: one-third becomes exercisable on February 14, 2026, another third on November 16, 2026, and the final third on November 16, 2027. Following this grant, she holds these derivative securities directly.
Humacyte (HUMA) filed its Q3 2025 report, showing early commercialization of Symvess. Total Q3 revenue was $753 (in thousands), including $703 from product sales and $50 from contracts. Cost of goods sold was $260. Operating expenses declined year over year, with R&D at $17,273 and SG&A at $7,610. Loss from operations narrowed to $(24,390), and net loss improved to $(17,510), helped by gains in fair-value items.
Year to date, revenue reached $1,571, while the net loss was $(16,029). Cash and cash equivalents were $19,488 at September 30, 2025. The company amended its Revenue Interest Purchase Agreement and made a $50.0 million repayment using previously restricted cash, eliminating that restriction as of quarter-end. Management believes cash on hand and remaining capacity under its equity line are sufficient for at least twelve months from issuance.
The company began capitalizing Symvess inventory in early 2025, recording $18.4 million as of quarter-end. Availability remained under financing programs, with $47.5 million left on the equity line and $62.7 million under the ATM facility.
Humacyte, Inc. furnished an 8‑K announcing that it issued a press release with financial results for its fiscal third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference. The company states the information under Item 2.02, including the exhibit, is furnished and not deemed “filed” under the Exchange Act.
Humacyte’s securities trade as HUMA (common stock) and HUMAW (warrants) on Nasdaq.
Humacyte, Inc. filed an 8-K reporting a material event that includes a Securities Purchase Agreement dated October 6, 2025 between the company and certain investors, and a Placement Agent Agreement dated October 6, 2025 with D. Boral Capital LLC. The filing also lists a Form of Warrant, legal opinion and consent from Covington & Burling LLP, and a press release dated October 7, 2025. The document identifies the company’s Chief Financial Officer, Chief Corporate Development Officer and Treasurer as signatory roles. No transaction amounts, share counts, or pricing terms are disclosed in the provided text.
Humacyte, Inc. reported a material event on an Form 8-K documenting Amendment No. 2 to a Revenue Interest Purchase Agreement executed on September 17, 2025. The amendment names the parties as Humacyte Global, Inc., Humacyte, Inc. and the purchasers TPC Investments III LP, TPC Investment Solutions LP and Hook SA LLC.
The filing indicates the inclusion of the amendment as an exhibit and an Inline XBRL cover page file. No financial terms, changes to covenants, or quantitative impacts were disclosed in the provided text, so the filing primarily records the contractual amendment rather than operational results.
Brady W. Dougan, a director of Humacyte, Inc. (HUMA), reported sales of common stock executed by Ayabudge LLC, an entity he controls. Between 08/18/2025 and 08/20/2025 Ayabudge sold a total of 2,241,045 shares in multiple transactions at weighted average prices of $1.83, $1.63 and $1.58 per share (per-footnote ranges: $1.79–$1.92, $1.57–$1.76, $1.53–$1.69). After the reported transactions Ayabudge beneficially owned 0 shares. The filing shows Mr. Dougan retains indirect beneficial ownership of 243,851 shares through his spouse and 1,148,240 shares through The Niklason Living Trust.
Laura E. Niklason, President, CEO and Director of Humacyte, Inc. (HUMA), reported changes in beneficial ownership on Form 4 related to sales of common stock held indirectly by Ayabudge LLC, an entity controlled by Brady W. Dougan. The filing discloses three groups of sales: 549,360 shares on 08/18/2025 at a weighted average price of $1.83, 1,100,000 shares on 08/19/2025 at a weighted average price of $1.63, and 591,685 shares on 08/20/2025 at a weighted average price of $1.58. Following the reported transactions, Ayabudge LLC's indirect holdings of those shares were reduced to zero. The filing also shows direct ownership of 243,851 shares and indirect ownership of 1,148,240 shares held by The Niklason Living Trust. The explanatory notes state the sales were executed by Ayabudge LLC to allow Mr. Dougan to pay down leverage and to provide a mechanism for investors to acquire shares; Dr. Niklason did not directly sell any shares. The Form 4 is signed on behalf of Dr. Niklason by an attorney-in-fact.
Humacyte, Inc. (HUMA) Form 144 reports a proposed sale of 591,685 common shares valued at $936,653.92 to be sold approximately on 08/20/2025 through UBS Financial Services on NASDAQ. The filer states the shares were originally acquired on 08/26/2021 as an early-stage investor position converted to Humacyte shares upon the company’s SPAC transaction; the original block purchased was 18,930,004 shares and payment was in cash. The filing also discloses recent dispositions by AYABUDGE LLC of 549,360 shares on 08/18/2025 (gross proceeds $997,429) and 1,100,000 shares on 08/19/2025 (gross proceeds $1,790,244). The filer certifies no undisclosed material adverse information.
Humacyte, Inc. notice of proposed sale reports an intended sale of 1,100,000 common shares through UBS Financial Services on or about 08/19/2025 on NASDAQ, with an aggregate market value of $1,790,244.50. The filing shows the shares were originally acquired on 08/26/2021 as early-stage investor holdings converted to Humacyte shares when the company went public via a SPAC, and payment for the original acquisition was in cash. The filer also reported sales during the prior three months: 549,360 shares sold on 08/18/2025 for gross proceeds of $997,429. The filing includes the filers representation that no undisclosed material adverse information is known.
Form 144 notice for HUMA (Humacyte, Inc.) reporting a proposed sale of common stock. The filer plans to sell 549,360 shares through UBS Financial Services Inc. on or about 08/18/2025, with an aggregate market value of $1,002,928.10. The company has 158,372,173 shares outstanding. The securities were originally acquired on 08/26/2021 as an early-stage investment in AHAC and converted to Humacyte shares when the company went public via SPAC; the original acquired amount shown is 18,930,004 shares with payment listed as cash. No securities were reported sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.